Product Information
MILI 0.25-0.035 MG TABLET is a generic product labeled by Aurobindo Pharma Limited, priced at $0.1148 per EA under NDC 65862077628. Its NADAC has been published 207 times since Oct 19, 2022.
FDA first approved this application on Jul 7, 2016. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Manufacturer
Aurobindo Pharma LimitedNDC
65862077628
Classification
Generic
Dosage Form
KIT
Effective Date
9/23/2026
Approval Type
Generic (ANDA)
FDA Application
ANDA205449FDA Approved
7/7/2016
TE Code
AB
On Market Since
7/7/2016
Price Statistics
The NADAC for MILI 0.25-0.035 MG TABLET has been published 207 times since Oct 19, 2022, and over the history we have for it it has declined 22.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1148 per EA |
|---|---|
| All-time high | $0.1552 (Sep 13, 2023) |
| All-time low | $0.1011 (Nov 20, 2024) |
| 52-week high | $0.1275 |
| 52-week low | $0.1148 |
| Median price | $0.1278 |
| Average price | $0.1287 |
| Largest weekly change | -21.9% (Nov 20, 2024) |
| Weeks tracked | 207 |
| Tracking since | Oct 19, 2022 |
Generic Alternatives
The matcher finds 8 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 6% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Aurobindo Pharma Limited manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
norgestimate and ethinyl estradiol market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of MILI 0.25-0.035 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for MILI 0.25-0.035 MG TABLET, manufactured by Aurobindo Pharma Limited, is $0.1148 per EA (NDC 65862077628), effective Sep 30, 2026.
How has the price of MILI 0.25-0.035 MG TABLET changed over time?
Over the history we have for it, the NADAC for MILI 0.25-0.035 MG TABLET has declined 22.8%. It has been tracked across 207 weekly CMS publications since Oct 19, 2022.
What are the highest and lowest recorded NADAC prices for MILI 0.25-0.035 MG TABLET?
Since Oct 19, 2022, the NADAC for MILI 0.25-0.035 MG TABLET has ranged from a low of $0.1011 (Nov 20, 2024) to a high of $0.1552 (Sep 13, 2023), with a median of $0.1278 per EA.
Are there cheaper alternatives to MILI 0.25-0.035 MG TABLET?
Yes. 8 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, TRI-LO-ESTARYLLA TABLET, is $0.1080 per EA — about 6% below MILI 0.25-0.035 MG TABLET.
Who manufactures MILI 0.25-0.035 MG TABLET?
MILI 0.25-0.035 MG TABLET (NDC 65862077628) is labeled by Aurobindo Pharma Limited, and CMS classifies it as a generic product.